Last 12 months
Inside the activity.
0 purchase rows · 6 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 4 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 07, 2021 Filed May 11, 2021 21:05 UTC |
FREYMAN THOMAS CDirector
|
GrantCommon Stock, $0.01 par value | 1,681 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-005201 · edgar.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,355 F1 · shares: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| May 07, 2021 Filed May 11, 2021 21:06 UTC |
Hart Brett JDirector
|
GrantCommon Stock, $0.01 par value | 1,681 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-005204 · edgar.xml · nonDerivative · entry 1 Hart Brett J · CIK 0001466338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,076 F1 · shares: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| May 07, 2021 Filed May 11, 2021 21:06 UTC |
MEYER MELODY BDirector
|
GrantCommon Stock, $0.01 par value | 1,681 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-005205 · edgar.xml · nonDerivative · entry 1 MEYER MELODY B · CIK 0001706126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,102 F1 · shares: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| May 07, 2021 Filed May 11, 2021 21:06 UTC |
RAPP EDWARD JDirector
|
GrantCommon Stock, $0.01 par value | 1,681 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-005206 · edgar.xml · nonDerivative · entry 1 RAPP EDWARD J · CIK 0001171780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,163 F1 · shares: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| May 07, 2021 Filed May 11, 2021 21:07 UTC |
Roberts Rebecca BDirector
|
GrantCommon Stock, $0.01 par value | 1,681 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-005207 · edgar.xml · nonDerivative · entry 1 Roberts Rebecca B · CIK 0001355580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,332 F1 · shares: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| May 07, 2021 Filed May 11, 2021 17:07 UTC |
TILTON GLENN FDirector
|
GrantCommon Stock, $0.01 par value | 1,681 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-005208 · edgar.xml · nonDerivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,168 F1 · shares: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| May 07, 2021 Filed May 11, 2021 21:07 UTC |
WADDELL FREDERICK HDirector
|
GrantCommon Stock, $0.01 par value | 1,681 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-005209 · edgar.xml · nonDerivative · entry 1 WADDELL FREDERICK H · CIK 0001223690 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,562 F1 · shares: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| May 03, 2021 Filed May 5, 2021 20:23 UTC |
Strom Carrie CSVP & Pres Global Allerg Aesth
|
Exercise / conversionOption (right to buy) · Derivative | 4,184 | $0.00 Strike: $41.39 | $0.00 |
DisclosureSEC source: 0001179110-21-004898 · edgar.xml · derivative · entry 3 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,184 shares Expires 2021-08-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 03, 2021 Filed May 5, 2021 20:23 UTC |
Strom Carrie CSVP & Pres Global Allerg Aesth
|
SaleCommon Stock, $0.01 par value | 4,184 | $112.40 | $470,281.60 |
DisclosureSEC source: 0001179110-21-004898 · edgar.xml · nonDerivative · entry 2 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,225 Read SEC document |
| May 03, 2021 Filed May 5, 2021 20:23 UTC |
Strom Carrie CSVP & Pres Global Allerg Aesth
|
Exercise / conversionCommon Stock, $0.01 par value | 4,184 | $41.39 | $173,175.76 |
DisclosureSEC source: 0001179110-21-004898 · edgar.xml · nonDerivative · entry 1 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2021 Filed Apr 1, 2021 20:43 UTC |
RAPP EDWARD JDirector
|
GrantStock Equivalent Units · Derivative | 325 | $108.22 Strike: $108.22 | $35,171.50 |
DisclosureSEC source: 0001179110-21-003954 · edgar.xml · derivative · entry 1 RAPP EDWARD J · CIK 0001171780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,855 Underlying: Common Stock · 325 shares Expires not disclosed F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| March 31, 2021 Filed Apr 1, 2021 16:43 UTC |
LIDDY EDWARD MDirector
|
GrantStock Equivalent Units · Derivative | 311 | $108.22 Strike: $108.22 | $33,656.42 |
DisclosureSEC source: 0001179110-21-003956 · edgar.xml · derivative · entry 1 LIDDY EDWARD M · CIK 0001188983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,094 Underlying: Common Stock · 311 shares Expires not disclosed F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| March 31, 2021 Filed Apr 1, 2021 20:43 UTC |
Alpern Robert JDirector
|
GrantStock Equivalent Units · Derivative | 66 | $108.22 Strike: $108.22 | $7,142.52 |
DisclosureSEC source: 0001179110-21-003957 · edgar.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,764 Underlying: Common stock · 66 shares Expires not disclosed F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| March 07, 2021 Filed Mar 9, 2021 22:26 UTC |
Strom Carrie CSVP & Pres Global Allerg Aesth
|
Tax withholdingCommon Stock, $0.01 par value | 123 | $106.70 | $13,124.10 |
DisclosureSEC source: 0001179110-21-003128 · edgar.xml · nonDerivative · entry 3 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,225 Read SEC document |
| March 06, 2021 Filed Mar 9, 2021 22:26 UTC |
Strom Carrie CSVP & Pres Global Allerg Aesth
|
Tax withholdingCommon Stock, $0.01 par value | 356 | $106.70 | $37,985.20 |
DisclosureSEC source: 0001179110-21-003128 · edgar.xml · nonDerivative · entry 2 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,348 Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 22:26 UTC |
Strom Carrie CSVP & Pres Global Allerg Aesth
|
Tax withholdingCommon Stock, $0.01 par value | 448 | $105.65 | $47,331.20 |
DisclosureSEC source: 0001179110-21-003128 · edgar.xml · nonDerivative · entry 1 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,704 Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 01:25 UTC |
Strom Carrie CSVP & Pres Global Allerg Aesth
|
Tax withholdingCommon Stock, $0.01 par value | 810 | $108.41 | $87,812.10 |
DisclosureSEC source: 0001179110-21-002588 · edgar.xml · nonDerivative · entry 1 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,152 Read SEC document |
| March 02, 2021 Filed Mar 2, 2021 20:27 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
Exercise / conversionOption (Right To Buy) · Derivative | 170,113 | $54.86 Strike: $0.00 | $9,332,399.18 |
DisclosureSEC source: 0001179110-21-002596 · edgar.xml · derivative · entry 9 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 170,113 shares Expires 2026-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| March 02, 2021 Filed Mar 2, 2021 20:27 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
Exercise / conversionCommon Stock, $0.01 par value | 170,113 | $54.86 | $9,332,399.18 |
DisclosureSEC source: 0001179110-21-002596 · edgar.xml · nonDerivative · entry 3 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 546,710 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 01:26 UTC |
Stewart Jeffrey RyanSVP, US Commercial Operations
|
SaleCommon Stock, $0.01 par value | 13,773 | $108.59 | $1,495,575.64 |
DisclosureSEC source: 0001179110-21-002594 · edgar.xml · nonDerivative · entry 2 Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,969 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.34 to $108.88 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 20:27 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
SaleCommon Stock, $0.01 par value | 631 | $109.33 | $68,984.08 |
DisclosureSEC source: 0001179110-21-002596 · edgar.xml · nonDerivative · entry 5 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 376,597 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.25 to $109.38 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 20:27 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
SaleCommon Stock, $0.01 par value | 169,482 | $108.61 | $18,407,219.69 |
DisclosureSEC source: 0001179110-21-002596 · edgar.xml · nonDerivative · entry 4 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377,228 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.207 to $109.20 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 01:30 UTC |
Sorg Elaine K.SVP, US Commercial Operations
|
SaleCommon Stock, $0.01 par value | 4,221 | $108.61 | $458,436.90 |
DisclosureSEC source: 0001179110-21-002603 · edgar.xml · nonDerivative · entry 3 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,595 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.35 to $108.83 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 01:30 UTC |
Sorg Elaine K.SVP, US Commercial Operations
|
SaleCommon Stock, $0.01 par value | 4,219 | $108.61 | $458,205.34 |
DisclosureSEC source: 0001179110-21-002603 · edgar.xml · nonDerivative · entry 2 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,816 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.35 to $108.83 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 01:31 UTC |
RICHMOND TIMOTHY J.EVP, Chief HR Officer
|
SaleCommon Stock, $0.01 par value | 19,514 | $108.59 | $2,119,040.87 |
DisclosureSEC source: 0001179110-21-002607 · edgar.xml · nonDerivative · entry 2 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.285 to $108.83, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 28, 2021 Filed Mar 3, 2021 01:25 UTC |
Schumacher Laura JVice Chairman
|
Tax withholdingCommon Stock, $0.01 par value | 29,203 | $107.74 | $3,146,331.22 |
DisclosureSEC source: 0001179110-21-002589 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,253 Read SEC document |
| February 28, 2021 Filed Mar 3, 2021 01:26 UTC |
SEVERINO MICHAELVice Chairman
|
Tax withholdingCommon Stock, $0.01 par value | 29,077 | $107.74 | $3,132,755.98 |
DisclosureSEC source: 0001179110-21-002592 · edgar.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,835 Read SEC document |
| February 28, 2021 Filed Mar 3, 2021 01:26 UTC |
Stewart Jeffrey RyanSVP, US Commercial Operations
|
Tax withholdingCommon Stock, $0.01 par value | 10,957 | $107.74 | $1,180,507.18 |
DisclosureSEC source: 0001179110-21-002594 · edgar.xml · nonDerivative · entry 1 Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,742 Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 20:27 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
Tax withholdingCommon Stock, $0.01 par value | 74,384 | $107.74 | $8,014,132.16 |
DisclosureSEC source: 0001179110-21-002596 · edgar.xml · nonDerivative · entry 2 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 376,597 Read SEC document |
| February 28, 2021 Filed Mar 3, 2021 01:29 UTC |
Hudson Thomas JSVP, R&D and CSO
|
Tax withholdingCommon Stock, $0.01 par value | 7,740 | $107.74 | $833,907.60 |
DisclosureSEC source: 0001179110-21-002599 · edgar.xml · nonDerivative · entry 1 Hudson Thomas J · CIK 0001781947 · SVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,372 Read SEC document |
| February 28, 2021 Filed Mar 3, 2021 01:29 UTC |
Durkin Brian LVP, Controller
|
Tax withholdingCommon Stock, $0.01 par value | 2,392 | $107.74 | $257,714.08 |
DisclosureSEC source: 0001179110-21-002601 · edgar.xml · nonDerivative · entry 1 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,115 Read SEC document |
| February 28, 2021 Filed Mar 3, 2021 01:30 UTC |
Sorg Elaine K.SVP, US Commercial Operations
|
Tax withholdingCommon Stock, $0.01 par value | 6,716 | $107.74 | $723,581.84 |
DisclosureSEC source: 0001179110-21-002603 · edgar.xml · nonDerivative · entry 1 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,035 Read SEC document |
| February 28, 2021 Filed Mar 3, 2021 01:31 UTC |
SALEKI-GERHARDT AZITAEVP, Operations
|
Tax withholdingCommon Stock, $0.01 par value | 15,785 | $107.74 | $1,700,675.90 |
DisclosureSEC source: 0001179110-21-002605 · edgar.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,284 Read SEC document |
| February 28, 2021 Filed Mar 3, 2021 01:31 UTC |
RICHMOND TIMOTHY J.EVP, Chief HR Officer
|
Tax withholdingCommon Stock, $0.01 par value | 15,524 | $107.74 | $1,672,555.76 |
DisclosureSEC source: 0001179110-21-002607 · edgar.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,514 Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 20:32 UTC |
Michael Robert A.EVP, Chief Financial Officer
|
Tax withholdingCommon Stock, $0.01 par value | 14,006 | $107.74 | $1,509,006.44 |
DisclosureSEC source: 0001179110-21-002608 · edgar.xml · nonDerivative · entry 1 Michael Robert A. · CIK 0001699914 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,877 Read SEC document |
| February 28, 2021 Filed Mar 3, 2021 01:34 UTC |
Gosebruch Henry OEVP, Chief Strategy Officer
|
Tax withholdingCommon Stock, $0.01 par value | 22,833 | $107.74 | $2,460,027.42 |
DisclosureSEC source: 0001179110-21-002611 · edgar.xml · nonDerivative · entry 1 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,711 Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 20:27 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
GiftCommon Stock, $0.01 par value | 3,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002596 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,981 Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 23:28 UTC |
Sorg Elaine K.SVP, US Commercial Operations
|
Exercise / conversionOption (right to buy) · Derivative | 5,192 | $0.00 Strike: $79.02 | $0.00 |
DisclosureSEC source: 0001179110-21-002251 · edgar.xml · derivative · entry 6 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,192 Underlying: Common Stock · 5,192 shares Expires 2029-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 23:28 UTC |
Sorg Elaine K.SVP, US Commercial Operations
|
Exercise / conversionOption (right to buy) · Derivative | 15,003 | $0.00 Strike: $93.50 | $0.00 |
DisclosureSEC source: 0001179110-21-002251 · edgar.xml · derivative · entry 5 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,005 Underlying: Common stock · 15,003 shares Expires 2030-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 23:28 UTC |
Sorg Elaine K.SVP, US Commercial Operations
|
SaleCommon Stock, $0.01 par value | 200 | $105.28 | $21,056.00 |
DisclosureSEC source: 0001179110-21-002251 · edgar.xml · nonDerivative · entry 4 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,751 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.26 to $105.31, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 23:28 UTC |
Sorg Elaine K.SVP, US Commercial Operations
|
SaleCommon Stock, $0.01 par value | 19,995 | $104.71 | $2,093,676.45 |
DisclosureSEC source: 0001179110-21-002251 · edgar.xml · nonDerivative · entry 3 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,951 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.25 to $105.24 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 23:28 UTC |
Sorg Elaine K.SVP, US Commercial Operations
|
Exercise / conversionCommon Stock, $0.01 par value | 5,192 | $79.02 | $410,271.84 |
DisclosureSEC source: 0001179110-21-002251 · edgar.xml · nonDerivative · entry 2 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,946 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 23:28 UTC |
Sorg Elaine K.SVP, US Commercial Operations
|
Exercise / conversionCommon Stock, $0.01 par value | 15,003 | $93.50 | $1,402,780.50 |
DisclosureSEC source: 0001179110-21-002251 · edgar.xml · nonDerivative · entry 1 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:15 UTC |
Durkin Brian LVP, Controller
|
GrantOption (right to buy) · Derivative | 15,527 | $0.00 Strike: $105.92 | $0.00 |
DisclosureSEC source: 0001179110-21-002042 · edgar.xml · derivative · entry 5 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,527 Underlying: Common stock · 15,527 shares Expires 2031-02-17 F6 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 5,176 on February 18, 2022, 5,176 on February 18, 2023, and 5,175 on February 18, 2024. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:15 UTC |
Durkin Brian LVP, Controller
|
GrantCommon Stock, $0.01 par value | 3,743 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002042 · edgar.xml · nonDerivative · entry 4 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,507 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:15 UTC |
Durkin Brian LVP, Controller
|
GrantCommon Stock, $0.01 par value | 1,897 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002042 · edgar.xml · nonDerivative · entry 3 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,764 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:15 UTC |
Durkin Brian LVP, Controller
|
GrantCommon Stock, $0.01 par value | 574 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002042 · edgar.xml · nonDerivative · entry 2 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,867 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:15 UTC |
Durkin Brian LVP, Controller
|
GrantCommon Stock, $0.01 par value | 1,955 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002042 · edgar.xml · nonDerivative · entry 1 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,293 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. F5 · balance_after: The total shown in this column reflects an update to correct a previous administrative error in the amount of securities beneficially owned by the reporting person. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:16 UTC |
Strom Carrie CSVP & Pres Global Allerg Aesth
|
GrantOption (right to buy) · Derivative | 32,298 | $0.00 Strike: $105.92 | $0.00 |
DisclosureSEC source: 0001179110-21-002043 · edgar.xml · derivative · entry 1 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,298 Underlying: Common stock · 32,298 shares Expires 2031-02-17 F1 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 10,766 on February 18, 2022 10,766 on February 18, 2023, and 10,766 on February 18, 2024. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:17 UTC |
Sorg Elaine K.SVP, US Commercial Operations
|
GrantOption (right to buy) · Derivative | 22,981 | $0.00 Strike: $105.92 | $0.00 |
DisclosureSEC source: 0001179110-21-002044 · edgar.xml · derivative · entry 5 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,981 Underlying: Common stock · 22,981 shares Expires 2031-02-17 F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,661 on February 18, 2022 7,660 on February 18, 2023, and 7,660 on February 18, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.